Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

Inclusion Criteria : * Healthy infants 2 months of age. * Infants with at least 37 weeks of gestation at delivery. * Signed informed consent from parent or guardian. * Able to attend the scheduled visits and to comply with the study procedure. * Subjects must have received the first dose of hepatitis B vaccine from birth to 28 days prior to the first dose of DAPTACEL or Pentacel. Exclusion Criteria : * Clinically significant findings on review of systems or physical examination (determined by investigator or sub-investigator to be sufficient for exclusion). * Known or suspected hypersensitivity to any component of the study vaccine to be administered. * Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth. * Known HIV-positive mother. * Personal or immediate family history of congenital immune deficiency. * Developmental delay or neurologic disorders. * Chronic medical, congenital, developmental or surgical disease. * Participation in any other experimental vaccine trial. * Any condition which, in the opinion of the investigator or sub-investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject. * Prior history of having received more than one dose of hepatitis B vaccine, any diphtheria, tetanus and acellular pertussis combination vaccine (DTaP), diphtheria, tetanus and whole-cell pertussis combination vaccine (DTwP), Haemophilus influenzae type b (Hib)-conjugate vaccine, poliovirus vaccine or pneumococcal conjugate vaccine